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Background: Under-diagnosis of COPD is an important unmet medical need. We investigated the characteristics
and prognosis of hospitalised patients with undiagnosed COPD.
Methods: The PAC-COPD cohort included 342 COPD patients hospitalised for the first time for an exacerbation of
COPD (2004–2006). Patients were extensively characterised using sociodemographic, clinical and functional variables,
and the cohort was followed-up through 2008. We defined “undiagnosed COPD” by the absence of any self-reported
respiratory disease and regular use of any pharmacological respiratory treatment.
Results: Undiagnosed COPD was present in 34% of patients. They were younger (mean age 66 vs. 68 years, p = 0.03),
reported fewer symptoms (mMRC dyspnoea score, 2.1 vs. 2.6, p < 0.01), and had a better health status (SGRQ total
score, 29 vs. 40, p < 0.01), milder airflow limitation (FEV1% ref., 59% vs. 49%, p < 0.01), and fewer comorbidities (two or
more, 40% vs. 56%, p < 0.01) when compared with patients with an established COPD diagnosis. Three months after
hospital discharge, 16% of the undiagnosed COPD patients had stopped smoking (vs. 5%, p = 0.019). During follow-up,
annual hospitalisation rates were lower in undiagnosed COPD patients (0.14 vs. 0.25, p < 0.01); however, this difference
disappeared after adjustment for severity. Mortality was similar in both groups.
Conclusions: Undiagnosed COPD patients have less severe disease and lower risk of re-hospitalisation when compared
with hospitalised patients with known COPD.
Keywords: Pulmonary disease, Chronic obstructive, Hospitalisation, Cohort studies, Epidemiology, Health servicesBackground
Chronic obstructive pulmonary disease (COPD) represents
a major public health problem, and its mortality and dis-
ability burden is expected to rise in the coming decades
[1,2]. Nonetheless, the majority of studies from general
population and primary care have detected that a high pro-
portion of individuals fulfilling COPD diagnosis criteria re-
main undiagnosed [3-9]. Interestingly, it has been reported* Correspondence: jgarcia@creal.cat
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unless otherwise stated.that a high proportion of undiagnosed patients already suf-
fer from respiratory symptoms [7,8]. A recent population-
based study demonstrated that even newly diagnosed
COPD patients with mild airflow limitation exhibit a sig-
nificant impairment in their health-related quality of life
and certain activities of daily living, when compared with
individuals without COPD [9]. Therefore, both researchers
and practitioners advocate for early detection strategies
aimed at reducing COPD burden through proven health-
care interventions [10].
There is a lack of specific information regarding COPD
under-diagnosis in patients requiring hospitalisation be-
cause of an exacerbation of the disease. Two previous
studies in a hospital setting highlighted that one-third of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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studies involved patients who went to the emergency
room for COPD exacerbation, and the second study was a
small retrospective study of patients admitted to the hos-
pital for the first time for a COPD exacerbation [11,12].
The current study describes the characteristics of COPD
patients who were undiagnosed at the time of their first
hospital admission because of a COPD exacerbation and
their short- and long-term outcomes.
Methods
Study design and ethics
This study was a longitudinal observational analysis con-
ducted within the Phenotype and Course of COPD Project
(PAC-COPD) [13]. Briefly, the PAC-COPD study included
all patients admitted to nine teaching hospitals in Spain
between January 2004 and March 2006 for a first-time
COPD exacerbation.
The study design is diagrammed in Figure 1 and in-
cluded the following features: (i) a recruitment visit (atSociodemographic variables
Smoking status
Ever,
Diagnosis of respiratory disease
In the previous 12 months,
Pharmacological treatment
Health care use services
Current
Smoking status
Clinical and functional variables
Re-hospitalisations
Mortality
Figure 1 Design and study population. *Until Dec 31, 2007 (re-hospitalisfirst hospitalisation due to COPD exacerbation) to obtain
sociodemographic variables, smoking status, information
about diagnosis and treatment previous to their first hospi-
talisation, and use of health services during the 12 months
preceding their first hospitalisation; (ii) a visit under stable
conditions (at least three months after discharge) to collect
clinical and functional variables and smoking status; and
(iii) a prospective 4-year active follow-up to obtain informa-
tion about re-hospitalisations and mortality.
During hospitalisation and at discharge, patients re-
ceived standard information about their disease, smoking
cessation advice, as well as pharmacological and non-
pharmacological treatment from the attending physician
according to local guidelines [14].
The study was approved by the Ethics Committees of
all participating hospitals and all patients gave their writ-
ten informed consent. All patients were actively followed
until death or December 31, 2008.
Additional details about the recruitment and follow-up
processes have been previously published [13,15,16].Newly
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A diagnosis of COPD was confirmed by spirometry at
least three months after discharge when the patient had
reached clinical stability. COPD was identified as a post-
bronchodilator forced expiratory volume in one second
to forced vital capacity ratio (FEV1/FVC) of less than 0.7
[17]. At recruitment (first hospitalisation due to COPD
exacerbation), patients were asked about their diagnosis
with “any respiratory disease” using the following ques-
tions: “Are you suffering from any respiratory disease?”,
“What is the name of your respiratory disease?”, “When
were you diagnosed with this respiratory disease?”, and
“Who diagnosed your respiratory disease?”. These ques-
tions were previously designed and pilot-tested in COPD
patients from the same geographical area [18]. Patients
reported any pharmacological treatments they were tak-
ing regularly (previous to hospitalisation) for any chronic
disease. We defined “undiagnosed COPD” as the absence
of any self-reported diagnosis of respiratory disease. In
addition, to reduce a potential misclassification due to
poor recall, we assumed that patients regularly using any
pharmacological respiratory treatment had been previ-
ously diagnosed. Once stable conditions were reached
and the diagnosis of COPD was confirmed, patients were
identified as “newly diagnosed” COPD patients. Details
on the exact wording of patients when describing their
respiratory disease, time from diagnosis, diagnosing doc-
tor, and respiratory treatment are reported in Additional
file 1: Table S1.
For our analysis, disease severity was classified accord-
ing to FEV1 levels as mild, moderate, severe and very se-
vere following the European Respiratory Society and the
American Thoracic Society (ERS/ATS) criteria [17].
Measurements
At recruitment, standardised epidemiological question-
naires were used to collect information on sociodemo-
graphic characteristics, smoking status, physical activity
(Spanish version of the Yale Physical Activity Survey) [19]
and health-care utilisation over the previous 12 months
[18]. The Charlson index of comorbidity was obtained
from medical records, patient recall and physical exa-
mination by an expert pulmonologist [20]. In addition, we
obtained the number of visits to a hospital emergency de-
partment, primary care emergency department, primary
care physician, primary care pulmonologist, and hospital-
based pulmonologist over the previous 12 months using
standardised epidemiological questionnaires.
When the patient was clinically stable after discharge,
the following measurements were obtained: forced spir-
ometry and bronchodilator test, static lung volumes by
whole-body plethysmography, diffusing capacity for car-
bon monoxide (DLco), arterial blood gases analysis while
breathing room air at rest, six-minute walking distance(6MWD), body mass index (BMI) and fat-free mass index
(FFMI). Patients also answered an epidemiological ques-
tionnaire, including a dyspnoea assessment using the
mMRC scale, to determine the patient’s smoking status
and current pharmacologic treatment information. Health-
related quality of life (HRQL) was assessed using the
validated Spanish version of St. George’s Respiratory
Questionnaire (SGRQ) [21]. Anxiety and depression
were evaluated with the Spanish version of the Hospital
Anxiety and Depression Scale (HADS) [22,23].
Detailed information on the methods and sources of
the questionnaires and the standardisation of the tests
used in the PAC-COPD study has been previously pub-
lished [13,16].
Re-hospitalisations and mortality during follow-up
Information on re-hospitalisations through December
31, 2007 (causes and dates) was obtained for all patients
from the Minimum Basic Dataset (CMBD), a national
administrative database. According to the 9th revision of
the International Classification of Diseases, an admission
for COPD exacerbation was defined as any admission with
codes 466, 480–486, 490–496, or 518.81 as the main diag-
nosis. Survival status until December 31, 2008 was ob-
tained from direct interviews with all patients or their
relatives. In cases of death, both hospital and primary care
registries were checked to verify the exact date.
Statistical analysis
The sample size was fixed by the primary scientific ob-
jectives of the PAC-COPD Study [16]. Before any ana-
lysis, we calculated whether the available number of
patients (225 patients in the diagnosed group and 117
in the undiagnosed group) would allow for identifica-
tion of clinically significant differences in outcome be-
tween groups (diagnosed vs. undiagnosed). Calculations
using the GRANMO 5.2 software [24] showed that,
accepting an alpha risk of 0.05 in a two-sided test, the
statistical power was 84 to recognize as statistically sig-
nificant the difference in proportion admitted (44% vs.
28%, respectively).
Descriptive data are presented as the number and per-
centage, the mean and standard deviation (SD), or the me-
dian and 25th or 75th percentiles, as appropriate. We
compared the sociodemographic and clinical variables and
use of healthcare resources prior to first hospitalisation ac-
cording to previous COPD diagnosis status, using Stu-
dent’s t-test or Mann–Whitney U test for quantitative
variables and a Chi squared or Fisher exact test for quali-
tative variables. We tested the effect of receiving a new
COPD diagnosis on quitting smoking by including an
interaction term between time (recruitment or stability
visit) and diagnosis in a logistic regression model that in-
cluded smoking and potential confounders (gender, age,
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quality of life, FEV1, arterial oxygen tension (PaO2)).
Kaplan-Meier curves of time to COPD readmission
were plotted according to COPD diagnosis status previous
to the baseline admission, and the log-rank test was used
to compare differences in readmission-free rates between
diagnosed and undiagnosed COPD patients [25]. Because
the proportionality assumption held, the association be-
tween previous COPD diagnosis and time to COPD re-
admission was assessed using Cox regression survival-
time models [26]. Multivariate models included as covari-
ates all potential confounders that were related to both
the exposure and the outcome, or modified the estimates
(>10% change in Hazard Ratio) for the remaining vari-
ables. Potential covariates included gender, age, maritalTable 1 Baseline characteristics of 342 COPD patients recruite
A
Age (years), m (SD)
Males, n (%)
Married, n (%)
Less than primary education, n (%)
Low socioeconomic status (IV-V), n (%)
Current workers, n (%)
Smoking status: current, n (%)
Pack-years, m (SD)
Physical activity (hours/week), m (SD)
≥2 comorbidities (Charlson index), n (%)
Severity of COPD (ERS/ATS), n (%)
Mild (FEV1≥ 80%)
Moderate (FEV1≥ 50%, <80%)
Severe (FEV1≥ 30%, <50%)
Very severe (FEV1 < 30%)
FEV1 post-bronchodilator (% pred), m (SD)
DLCO (% pred.), m (SD)
RV/TLC (%), m (SD)
PaO2 (mmHg), m (SD)
PaCO2 (mmHg), m (SD)
6MWD (m), median (P25-P75)
Dyspnoea score (mMRC, score 0–4), m (SD)
BMI (Kg/m2), m (SD)
FFMI (Kg/m2), m (SD)
SGRQ total score (0 no health impairment to 100 maximum impairment),
m (SD)
SGRQ symptoms score, m (SD)
ERS/ATS: European Respiratory Society/American Thoracic Society; FEV1: forced expi
forced vital capacity; RV/TLC: Residual Volume/Total Lung Capacity; DLCO: diffusing
carbon dioxide tension; 6MWD: six-minute walking distance; mMRC: modified Medi
St. George’s Respiratory Questionnaire. *Some variables had missing values: 25 in so
46 in DLCO, 11 in PaO2, 10 in PaCO2, 33 in 6MWD, 13 in FFMI, and four in SGRQ scostatus, smoking status, quality of life, degree of dyspnoea,
BMI, FFMI, the Charlson index of comorbidity, FEV1,
DLco, Residual Volume/Total Lung Capacity (RV/TLC),
PaO2, arterial carbon dioxide tension (PaCO2), 6MWD,
and anxiety and depression. The same approach was to be
used to assess the effect of undiagnosis on mortality; how-
ever, there were very few deaths during follow-up and this
multivariate analysis was not completed. Data analyses
were conducted using Stata 10.1 (StataCorp, College Sta-
tion, TX, USA).
Results
Characteristics of patients with undiagnosed COPD
The entire PAC-COPD cohort included 342 patients
(93% men) with a mean (SD) age of 67 (9) years and ad at their first hospitalisation for a COPD exacerbation
ll COPD patients
n = 342*
Undiagnosed COPD
n = 117 (34%)
Diagnosed COPD
n = 225 (66%)
p-value†
67 (9) 66 (9) 68 (8) 0.03
318 (93) 107 (92) 211(94) 0.43
274 (80) 90 (77) 184 (82) 0.29
142 (42) 46 (39) 96 (43) 0.55
259 (82) 90 (81) 169 (82) 0.83
61 (18) 30 (26) 31 (14) <0.01
150 (44) 69 (59) 81 (36) <0.01
69 (40) 67 (38) 70 (41) 0.55
33.5 (23.8) 39.5 (23.4) 30.4 (23.5) 0.01
172 (50) 47 (40) 125 (56) <0.01
19 (5) 14 (12) 5 (2) <0.01
164 (48) 65 (56) 99 (44)
132 (39) 33 (28) 99 (44)
27 (8) 5 (4) 22 (10)
52 (16) 59 (16) 49 (15) <0.01
65 (21) 67 (21) 64 (21) 0.23
56 (10) 52 (10) 58 (9) <0.01
74 (11) 75 (10) 74 (11) 0.28
41.8 (5.3) 42.2 (5.2) 41.6 (5.4) 0.37
437 (390–500) 440 (396–502) 437 (373–498) 0.25
2.40 (1.06) 2.06 (1.09) 2.59 (0.99) <0.01
28.2 (4.7) 28.8 (4.7) 27.9 (4.6) 0.08
19.7 (3.1) 19.9 (3.0) 19.5 (3.1) 0.21
37 (18) 29 (16) 40 (18) <0.01
48 (18) 45 (16) 50 (18) <0.01
ratory volume in 1 second; FEV1/FVC: forced expiratory volume in 1 second/
capacity for carbon monoxide; PaO2: arterial oxygen tension; PaCO2: arterial
cal Research Council; BMI: body mass index; FFMI: fat-free mass index; SGRQ:
cioeconomic status, one in physical activity, four in dyspnoea, 27 in RV/TLC,
re. †Comparison between undiagnosed and previously diagnosed COPD.
Balcells et al. BMC Pulmonary Medicine 2015, 15:4 Page 5 of 9
http://www.biomedcentral.com/1471-2466/15/4mean (SD) post-bronchodilator FEV1 of 52% (16%) pre-
dicted during clinical stability (Table 1). A total of 117
patients (34%) fulfilled the criteria of “undiagnosed
COPD”. Table 1 shows the comparisons of sociodemo-
graphic and clinical characteristics for these two groups.
Undiagnosed patients were younger and more physically
active, had fewer symptoms and better health status, and
had milder airflow limitation and fewer comorbidities; in
addition a higher proportion of these patients reported
that they currently smoked (Table 1). A total of 33 (28%)
patients with severe COPD and 5 (4%) patients with very
severe COPD reported that they had never been diag-
nosed as having a respiratory disease prior to their first
hospitalisation. The Charlson comorbidities are shown
in Additional file 1: Table S2.
Undiagnosed patients reported a significantly lower use
of health care resources due to respiratory symptoms in the
12 months prior to their first hospitalisation for a COPD
exacerbation. The number of unscheduled visits to the pri-
mary care surgery was similar in both groups (Table 2).
Short-term effects associated with a COPD diagnosis
Figure 2 shows the short-term effects associated with a
COPD diagnosis on smoking cessation. The proportion of
current smokers after hospital discharge decreased signifi-
cantly more in newly diagnosed COPD patients than in
those with a previous COPD diagnosis (16% vs. 5%). Des-
pite significantly different baseline values at hospitalisation
(Figure 2), the interaction between diagnosis group and
time was significant (p = 0.019).
Long-term prognosis of newly diagnosed COPD patients
During a mean (SD) of 1.87 (0.98) years of follow-up,
44% of previously diagnosed patients and 28% of newlyTable 2 Self-reported diagnosis, respiratory treatment and us
of 342 COPD patients in the 12 months prior to their first ho
COPD diagnosis and treatment
COPD diagnosis*
COPD treatment*
Use of health care resources due to respiratory symptoms in the
12 months prior to first COPD hospitalisation
At least one visit to hospital emergency department
At least one unscheduled visit to primary care
≥3 visits to any physician
≥3 visits to primary care physician
≥3 visits to primary care-based pulmonologist
≥3 visits to hospital-based pulmonologist
*See Additional file 1: Table S1 in for details.
†Comparison between undiagnosed and diagnosed COPD.diagnosed required re-hospitalisation. This corresponds
to 0.25 and 0.14 annual hospitalisation rates (p < 0.01),
respectively (Figure 3, panel A). However, this risk of re-
hospitalisation was similar in both groups after adjusting
for other covariates in a Cox regression multivariate
model (Table 3). The proportion of patients who re-
quired admission was higher in previously diagnosed pa-
tients when compared with newly diagnosed patients for
the mild, moderate and severe spirometric COPD groups
(20% vs. 7%, 36% vs. 23% and 49% vs. 36%, respectively).
The proportion of patients within the very severe COPD
group who required admission was 63% in previously di-
agnosed patients and 100% for newly diagnosed patients;
however, the very small sample size prevented any statis-
tical comparisons.
During a mean (SD) of 3.28 (0.85) years, overall sur-
vival rates (Figure 3, panel B) of previously diagnosed
and newly diagnosed patients were similar (87% and
84%, respectively; p = 0.51) at all severity stages (80%
and 93% in mild, 92% and 85% in moderate, 87% and
81% in severe, and 64% and 60% in very severe patients).
Discussion
This study has three main findings: (1) undiagnosed pa-
tients (34% of all patients hospitalised for the first time
because of an exacerbation of COPD) have milder air-
flow limitation, fewer symptoms, fewer comorbidities,
and better HRQL when compared with patients with a
previous diagnosis of COPD; (2) establishing a COPD
diagnosis is associated with a positive short-term effect
on smoking cessation; and (3) undiagnosed patients have
a lower risk of re-hospitalisations but a similar mortality
after hospitalisation when adjusted for severity of illness
and covariates.e of health care resources due to respiratory symptoms
spitalisation for a COPD exacerbation
All COPD
patients n = 342
Undiagnosed COPD
n = 117 (34%)
Diagnosed COPD
n = 225 (66%)
p-value†
n (%) n (%) n (%)
157 (46) – 157 (70) –
193 (56) – 193 (86) –
34 (10) 3 (3) 31 (14) <0.01
64 (19) 21 (18) 43 (19) 0.79
104 (31) 15 (13) 89 (40) <0.01
56 (16) 6 (5) 50 (22) <0.01
18 (5) 1 (1) 17 (8) <0.01
2 (1) 0 (0) 2 (1) 0.55
%
 c
ur
re
nt
 s
m
ok
er
s
Recruitment Clinical stability
Newly diagnosed
Previously diagnosed
pgroups=0.001
ptime=0.001
pinteraction=0.019
Figure 2 Short-term effects of a new COPD diagnosis on smoking cessation. P-values were obtained from a logistic regression model with
active smoking as the outcome and the interaction between diagnosis status and time (period) included as explanatory variables. For further
explanations, see the main manuscript text.
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frequently reported, both in population based-studies and
in primary care settings [3-9]. In contrast, there is little in-
formation available regarding COPD under-diagnosis in
hospitalised patients. Our study confirms that undiagnosed
COPD is not confined to the general population or primary
care. We determined that one-third of patients admitted
for the first time for a COPD exacerbation were undiag-
nosed. This finding is in accordance with a previous Italian
study of patients attending the emergency room because of
a COPD exacerbationand a retrospective study of patients
admitted in a UK hospital for the first time for a COPD ex-
acerbation [11,12]. Importantly, the hospital-based design
and the thorough characterisation of the patients in our
study prevented the inclusion of healthy subjects with age-
related airflow limitation.
The substantial differences observed between diagnosed
and undiagnosed patients deserve special consideration. In
our cohort, undiagnosed patients were younger, had less0
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Figure 3 Kaplan-Meier curves show the cumulative hospitalisation-fre
COPD diagnosis.severe airflow limitation and a better HRQL. These find-
ings confirm several previous population-based studies
with similar observations [8,9,27]. In contrast, Zoia et al.
did not find differences in age and severity based on previ-
ous COPD diagnosis in the hospital setting [11]; however,
their diagnosed patients had more comorbidities when
compared with undiagnosed patients [11]. It is possible
that the lack of diagnosis (hence, treatment) may have re-
sulted in an “earlier” first hospital admission for a COPD
exacerbation, when the patient still had mild-to-moderate
COPD [15]. In fact, our findings indicated that un-
diagnosed COPD may be related to a lack of primary care
interventions prior to the first admission (Table 3). Unfor-
tunately, specific information about these interventions,
such as smoking cessation advice, was not recorded in the
PAC-COPD study.
Similar to the report by Zoia et al., we identified a
higher proportion of current smokers in the undiag-
nosed group when compared with the diagnosed group0
.2
5
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1 year 2 years 3 years 4 years
Rate per person·year
0.04 (Previously diagnosed) vs 0.05 (Newly diagnosed), p=0.51
(B)
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Time to death
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e rate (panel A) and survival rate (panel B) according to previous
Table 3 Association between previous COPD diagnosis and subsequent COPD hospitalisations
Crude model Adjusted model*
HR (95% CI) p-value HR (95% CI) p-value
Previously diagnosed COPD 1.00 1.00
Newly diagnosed COPD 0.564 (0.380-0.836) <0.01 0.858 (0.551-1.338) 0.50
Dyspnoea score (mMRC, score 0–4) – – 1.234 (1.005-1.515) 0.04
BMI (Kg/m2) – – 0.961 (0.919-1.005) 0.08
RV/TLC (%) – – 1.025 (1.000-1.050) 0.04
FEV1 post-bronchodilator (% pred) – – 0.994 (0.977-1.011) 0.51
HR: hazard ratio; CI: confidence interval; mMRC: modified Medical Research Council; BMI: body mass index; RV/TLC: Residual Volume/Total Lung Capacity; FEV1:
forced expiratory volume in 1 second.
*Final models were adjusted to account for negative confounding, i.e., that the apparently protective effect of undiagnosed COPD is due to a lower clinical
severity of the disease. Other potential confounders (see text) were tested but not included because they were not independently related to both the exposure
and the outcome, nor did these confounders modify (>10% change in Hazard Ratio) the estimates for the remaining variables.
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COPD diagnosis was associated with a significant reduc-
tion in current smokers (Figure 2). This finding is simi-
lar to previous reports that showed that smokers with
airflow limitation had significantly higher smoking cessa-
tion rates than those with normal spirometry [28,29].
These data identify a potentially important window of
opportunity for therapeutic intervention.
The re-hospitalisation rate was lower in newly diagnosed
COPD patients following their first admission (Figure 3,
panel A); however, this decreased risk was not significant
after multivariable adjustments (Table 3), indicating that
the protective effect of undiagnosed COPD was likely due
to a lower severity of the disease. This interpretation is
challenged by the lack of differences in mortality during
follow-up (Figure 3, panel B), and a better prognosis is ex-
pected in undiagnosed patients with a milder disease.
Thus, this observation requires further research. One po-
tential explanation is that cardiovascular disease might
play a more relevant role in undiagnosed patients because
the majority were active smokers and had milder COPD.
This idea is supported by previous studies that consist-
ently showed the causes of death in patients with mild
COPD were predominantly cancer and cardiovascular
disease, while deaths due to respiratory disease became
more common with increasing COPD severity [30]. In our
study, there were very few deaths during follow-up. There-
fore, the sample size was too small to analyse differences
in cause of death between groups.
Clinical features and outcomes of newly diagnosed COPD
patients highlighted the clinical relevance of pursuing a cor-
rect diagnosis in all hospitalised patients and applying the
appropriate corresponding health measures. A recent report
by Suissa et al. [31] identified two strategic targets for the
management of COPD patients during their first hospital-
isation. First, the second hospitalisation should be delayed
as much as possible because subsequent exacerbations in-
crease exponentially in frequency and intensity. Second, im-
proved treatment is needed to reduce early mortality [31].Some limitations of our study should be addressed.
Firstly, self-reported information about COPD diagnosis
rather than objective medical records could lead to mis-
classification. Secondly, the very small number of un-
diagnosed patients with very severe COPD has limited
our analysis with regard to this specific subgroup. Fi-
nally, our results regarding the extent of COPD under-
diagnosis and the clinical profile of these patients may
not be able to be generalised to other health care sys-
tems; however, the effect of the lack of COPD diagnosis
on subsequent hospitalisations and mortality are likely
to be generally applicable.
The strengths of our study included the large cohort of
COPD patients, and their homogeneity with respect to in-
cipient COPD hospitalisations, the wide spectrum of dis-
ease severity, and length of follow up. Furthermore, the
comprehensive multidimensional assessment used in our
study allowed adjustments for potential confounders.
Conclusions
This study showed that approximately one-third of pa-
tients hospitalised for the first time because of a COPD
exacerbation had not been previously diagnosed (hence,
treated). In addition, patients generally exhibited less
severe disease, and their risk of re-hospitalisation was
lower when compared with patients who were hospita-
lised with an established COPD diagnosis. First admis-
sion due to COPD exacerbation provides a window of
opportunity for early treatment, in particular for smok-
ing cessation intervention.Additional file
Additional file 1: Table S1. Characteristics of respiratory diagnoses and
pharmacological treatments prior to the first admission for COPD
exacerbation in diagnosed COPD patients (n = 225). Table S2. Charlson
comorbidities in 342 COPD patients recruited at their first hospitalisation
for a COPD exacerbation. Comparison between undiagnosed and
previously diagnosed COPD patients.
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HADS: Hospital anxiety and depression scale; CMBD: Minimum Basic Dataset;
SD: Standard deviation; RV/TLC: Residual volume/total lung capacity;
PaO2: Arterial oxygen tension; PaCO2: Arterial carbon dioxide tension.
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